Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
The Pharma Data
APRIL 4, 2023
Biosimilars help patients to gain broader access to effective and high-quality treatments that improve their disease therapies,” said Rebecca Guntern, Head of Region Europe, Sandoz. Recently, US Food and Drug Administration (FDA) also approved the citrate-free HCF of Hyrimoz ® (adalimumab-adaz) injection.
40 
Let's personalize your content